Your browser doesn't support javascript.
loading
Comparative Effectiveness of an mTOR-Based Systemic Therapy Regimen in Advanced, Metaplastic and Nonmetaplastic Triple-Negative Breast Cancer.
Basho, Reva K; Yam, Clinton; Gilcrease, Michael; Murthy, Rashmi K; Helgason, Thorunn; Karp, Daniel D; Meric-Bernstam, Funda; Hess, Kenneth R; Valero, Vicente; Albarracin, Constance; Litton, Jennifer K; Chavez-MacGregor, Mariana; Hong, David; Kurzrock, Razelle; Hortobagyi, Gabriel N; Janku, Filip; Moulder, Stacy L.
Affiliation
  • Basho RK; Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Yam C; Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Gilcrease M; Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Murthy RK; Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Helgason T; Department of Investigational Cancer Therapeutics (Phase I Trials Program), The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Karp DD; Department of Investigational Cancer Therapeutics (Phase I Trials Program), The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Meric-Bernstam F; Department of Investigational Cancer Therapeutics (Phase I Trials Program), The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Hess KR; Department of Breast Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Valero V; Sheikh Khalifa Bin Zayed Al Nahyan Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Albarracin C; Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Litton JK; Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Chavez-MacGregor M; Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Hong D; Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Kurzrock R; Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Hortobagyi GN; Department of Health Services Research, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Janku F; Department of Investigational Cancer Therapeutics (Phase I Trials Program), The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Moulder SL; Department of Investigational Cancer Therapeutics (Phase I Trials Program), The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Oncologist ; 23(11): 1300-1309, 2018 11.
Article de En | MEDLINE | ID: mdl-30139837
Sujet(s)
Mots clés
Texte intégral
Ajouter à My VHL
Imprimer
XML
PubMed Links
Recherche sur Google

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Sérine-thréonine kinases TOR / Tumeurs du sein triple-négatives Type d'étude: Prognostic_studies Limites: Adult / Aged / Female / Humans / Middle aged Langue: En Journal: Oncologist Sujet du journal: NEOPLASIAS Année: 2018 Type de document: Article Pays d'affiliation: États-Unis d'Amérique
Texte intégral
Ajouter à My VHL
Imprimer
XML
PubMed Links
Recherche sur Google

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Sérine-thréonine kinases TOR / Tumeurs du sein triple-négatives Type d'étude: Prognostic_studies Limites: Adult / Aged / Female / Humans / Middle aged Langue: En Journal: Oncologist Sujet du journal: NEOPLASIAS Année: 2018 Type de document: Article Pays d'affiliation: États-Unis d'Amérique